Costimulatory B7 molecules (B7-1 or CD80; and B7-2 or CD86) are known to bind to T cell costimulatory receptors CD28 and CTLA4. Engagement of CD28 is know to transduce signals in T cells that play a critical role in T cell activation; however, little is known of the ability of B7 molecules to themselves act as signal transducing molecules. The effect of B7-1 and B7-2 crosslinking was assessed in the B cell lymphoma BAL.17. Initial studies demonstrated that B7 crosslinking induces AP-1 components including c-fos and c-jun, as demonstrated by gel retardation and """"""""super-shift"""""""" assays. These findings indicate that B7 engagement by counter-receptors such as CD28 or CTLA4 may lead to bidirectional effects, functioning to transduce signals in B7-expressing cells such as B lymphocytes, in addition to signaling CD28/CTLA4 positive T cells. The role of CD28/B7 interactions has been analyzed in host responses to antigenic tumor. EL4 tumor cells grew progressively in syngeneic B6 mice. However, transfection of EL4 with B7-1 or B7-2 costimulatory ligands resulted in tumor rejection and the induction of tumor-specific immunity. Tumor rejection under these conditions was dependent upon the presence of the B7 receptor CD28 as demonstrated using CD28-deficient B6 mice for tumor challenge. These results demonstrated for the first time the requirement for CD28 as a B7 receptor in tumor rejection. The role of B7 cytoplasmic domains in tumor rejection was tested by transfection of EL4 cells with cytoplasmic deletion mutants of B7-1 and B7-2, and it was found that tumor rejection was not influenced by the presence or absence of B7 cytoplasmic domains. These results indicate that CD28 interaction with extracellular B7-1 or B7-2 domains can mediate costimulatory function for syngeneic tumor rejection.
